Skip to main content
. 2010 Jul 1;69(7):1275–1280. doi: 10.1136/ard.2009.126888

Table 2.

Summary of secondary efficacy results

Median (range) IL-6 (IU/l) Mean (SD) pain VAS (mm) Mean (SD) DAS 28
Baseline MR IR MR IR MR IR
Start DB (N=288) 860 (200–23000) 1110 (200–20800) 51 (15) 52 (17) 5.8 (0.8) 5.9 (0.9)
n=142 n=142 n=141 n=143 n=144 n=142
MR/MR IR/MR MR/MR IR/MR MR/MR IR/MR
End OP (N=219) 470* (200–18300) 515* (200–8100) 40* (26) 39* (24) 4.8* (1.3) 4.9* (1.2)
n=103 n=114 n=98 n=107 n=103 n=115
*

As a non-parametric approach for the paired samples, Wilcoxon signed rank tests were applied to the absolute changes from baseline of the double-blind phase (p<0.05).

These data are from the double-blind phase.

Descriptive p values are given for the absolute changes from the baseline double-blind phase for available pairs of data.

DAS 28, disease activity score of 28 joints; DB, double-blind study phase; IL-6, interleukin 6; IR, immediate-release; MR, modified-release; n, number of available data; N, number of patients enrolled; OP, open-label extension phase; VAS, visual analogue scale.